NCT07046689Recruiting
PET/CT for Trop2 ADC Response Evaluation Cancers
Evaluation of Treatment Response to Trop2 ADC by 68Ga-MY6349 PET/CT in Advanced Breast Cancer
Source: ClinicalTrials.gov · Last updated 15 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
To evaluate whether serial 68Ga-MY6349 PET/CT imaging can serve as a noninvasive biomarker to predict the therapeutic efficacy of Trop2-targeted antibody-drug conjugate (Trop2-ADC) therapy in breast cancer patients.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 19 Jun 2025
- Start date
- 1 Nov 2024
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- The First Affiliated Hospital of Xiamen University
- Diseases
- Metastatic breast cancer
- NCT number
- NCT07046689
What you commit to
- Study type: Observational
- Planned participants: 50
- From 1 Nov 2024 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Evidence of significantly impaired hepatic or renal function
- Estimated life expectancy of less than 3 months
Who the study is looking for
- adult patients (aged 18 years or order)
- histologically or cytologically confirmed metastatic breast cancer previously treated with systemic therapy, supported by imaging (e.g., MRI, CT), tumor markers, or pathology reports
- presence of at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1
- willingness to undergo serial 68Ga-MY6349 PET/CT scans before and during Trop2-ADC therapy
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Ability to provide written informed consent and, where applicable, assent in accordance with the requirements of the Clinical Research Ethics Committee
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Affiliated hospital of Xiamen University Coordinator of this site? Confirm its status | Xiamen | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.